



Second Quarter 2014 Earnings July 31, 2014


ACORDA[®]
THERAPEUTICS

Forward Looking Statements

This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including our ability to successfully market and sell Ampyra in the U.S.; third party payers (including governmental agencies) may not reimburse for the use of Ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra or from our other research and development programs, including Plumiaz (our trade name for Diazepam Nasal Spray), or any other acquired or in-licensed programs; we may not be able to complete development of, obtain regulatory approval for, or successfully market Plumiaz or other products under development; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of or to successfully market Fampyra outside of the U.S. and our dependence on our collaboration partner Biogen Idec in connection therewith; competition, including the impact of generic competition on Zanaflex Capsules revenues; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; failure to comply with regulatory requirements could result in adverse action by regulatory agencies; and the ability to obtain additional financing to support our operations. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities & Exchange Commission. Acorda may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this presentation are made only as of the date hereof, and Acorda disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

Agenda

- AMPYRA® Update
- Pipeline Update
- Financial Results
- Corporate Growth Strategy




AMPYRA Update

ACORDA[®]
THERAPEUTICS

AMPYRA Update

- Q2 2014 net revenue \$87.4 million
- Reiterating AMPYRA U.S. net sales guidance of \$328-\$335 million
- 5 Orange Book patents extending to 2027
 - Filed patent infringement suits against ANDA filers
 - 30-month stay is effective until July 2017, unless district court issues a decision adverse to all asserted Orange Book patents prior to that date



Pipeline Update

Dalfampridine Post-Stroke Update

- Phase 3 study expected to begin in 2014 using BID dosing
 - Adaptive design with an interim look
- Working on a new QD formulation

Pipeline Update

- Engaging with FDA to finalize NDA re-filing requirements for PLUMIAZ™
- On track to begin NP-1998 Phase 3 trial in HIV-related neuropathy by end of 2014
- rHIgM22 Phase 1b trial in MS remyelination recruitment completed
 - Results expected early 2015
- GGF2 heart failure trial results expected in 2H 2015
- AC105 clinical trial in acute spinal cord injury ongoing



Financial Results

Financial Summary

(\$ in millions)

	Quarter Ended		Year to Date	
	<u>6/30/2014</u>	<u>6/30/2013</u>	<u>6/30/2014</u>	<u>6/30/2013</u>
Cash, cash equivalents, short and long-term investments	\$727.7	\$332.4	\$727.7	\$332.4
Net Ampyra revenue	\$87.4	\$77.8	\$159.9	\$140.1
Zanaflex branded/authorized generic revenue	\$2.1	\$2.3	\$3.8	\$4.1
Royalty revenue	\$5.1	\$4.7	\$8.9	\$10.2
Total revenues	\$97.1	\$87.1	\$177.6	\$158.9
Total operating expenses	\$86.2	\$78.3	\$163.3	\$152.7
Non-GAAP net income*	\$17.7	\$14.1	\$26.5	\$15.4

* 2013 revised to conform with current year presentation of excluding non-cash taxes for non-GAAP net income

This slide contains GAAP and non-GAAP financial measures. Non-GAAP net income excludes certain items. Information regarding our use of non-GAAP measures, a description of excluded items, and a reconciliation of those measures to GAAP is available in our financial results press release, which is now available in the investor relations section of our website at www.acorda.com.

Corporate Growth Strategy

- Continue to grow AMPYRA business
- Advance pipeline portfolio
- Acquire additional assets

Product Pipeline





Second Quarter 2014 Earnings July 31, 2014

ACORDA[®]
THERAPEUTICS